
Valeant Pharmaceuticals Completes Amended Credit Facility

Date: 09/11/12

Cahill represented the administrative agent in connection with the \$175,000,000 incremental revolving loan credit facility for Valeant Pharmaceuticals International, Inc. The loan will be added to Valeant's existing \$3,800,000 billion facility, comprised of a \$1,225,000,000 initial draw term loan, a \$275,000,000 revolving credit facility, a \$500,000,000 delayed draw term loan facility, a \$500,000,000 series A new term loan facility, and a \$1,300,000,000 tranche B term loan facility.

Attorneys

- Noah B. Newitz
- Josiah M. Slotnick
- Gregory J. Battista